Assessment and Treatment of Vaginitis

Obstet Gynecol. 2024 Dec 1;144(6):765-781. doi: 10.1097/AOG.0000000000005673. Epub 2024 Jul 11.

Abstract

Vaginitis is the presenting symptom at millions of office visits each year in the United States. Although treatment of sporadic cases is often straightforward, recurrent cases present both diagnostic and treatment challenges. Molecular diagnostic tests are likely superior to in-office microscopy for most clinicians and most cases. In both recurrent bacterial vaginosis and recurrent vulvovaginal candidiasis, national treatment guidelines recommend an extended treatment duration with one of the first-line agents. In cases in which such treatment is not successful, vaginal boric acid is likely the cheapest and easiest alternative option. New antifungal medications offer additional but limited treatment options. Probiotics are not recommended for prevention of vulvovaginal candidiasis; however, vaginal products containing Lactobacillus crispatus may have promise for recurrent bacterial vaginosis. Trichomoniasis should be treated with a 1-week course of metronidazole; this is the only sexually transmitted infection for which treatment recommendations vary by sex. In cases in which patients do not respond to initial treatment, the diagnosis should be reconsidered, and other potential causes such as desquamative inflammatory vaginitis, genitourinary syndrome of menopause, or vulvodynia should be considered.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Antifungal Agents / therapeutic use
  • Candidiasis, Vulvovaginal* / diagnosis
  • Candidiasis, Vulvovaginal* / drug therapy
  • Female
  • Humans
  • Metronidazole / therapeutic use
  • Vaginitis* / diagnosis
  • Vaginitis* / drug therapy
  • Vaginitis* / microbiology
  • Vaginitis* / therapy
  • Vaginosis, Bacterial / diagnosis
  • Vaginosis, Bacterial / drug therapy

Substances

  • Antifungal Agents
  • Metronidazole
  • Anti-Bacterial Agents